Britain and America have finalized a important bilateral deal that will preserve no import taxes on British pharmaceutical products being sold in the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This pledge ensures that tariffs on these key exports will stay at nothing for a timeframe of the next three years.
This deal follows previous threats to dramatically increase tariffs on patented drug imports, with increases floated up to 100%.
"This arrangement with the Britain strengthens the worldwide climate for innovative medicines and brings long-overdue equity to U.S.–U.K. drug exports," a release declared.
Commercial Impact
Pharmaceuticals are one of the Britain's largest export categories to the America, which is by far the primary destination for major UK drugmakers.
Trade data indicate that in the 12 months prior to September, the UK exported pharmaceutical products valued at £11.1bn to the US. This value represented 17.4% of British export trade in that timeframe.
"This guarantee safeguards work, boosts investment and facilitates the UK to become a global hub for life sciences," a minister commented.
Detailed British Pledges
The agreement includes several key pledges from the British government:
- Price Threshold Increase: The UK will lift the affordability limit at which it judges new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to increase total public funding on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must return to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds exceeded twenty percent.
Broader Context
This agreement takes place against a protracted row between the pharmaceutical industry and the ministers over spending levels and approval rates.
These tensions were exacerbated by assertions that US consumers were paying several times more for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or cancelled, while substantial investments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS must invest a greater share on treatments, noting that its spending on drugs had declined as a percentage of its total funding over the previous ten-year period.
